Theriva Biologics up on positive DSMC review in SYN-004 trial for transplant recipients [Seeking Alpha]
Theriva Biologics, Inc. (TOVX)
Company Research
Source: Seeking Alpha
review of early stage SYN-004 trial in transplant recipients to prevent graft-versus-host disease. Adverse events ((AEs)) and serious adverse events ((SAEs)) observed in Cohort 2 were typical of those observed in allo-HCT patients and no AEs or SAEs were determined by the investigators to be related to study drug treatment. A total of 15 SAEs were reported among 10 patients, with the most common SAE being infections and infestations, including sepsis. No patients died within the 30-day follow-up period after the last dose of study drug. 1 patient died 95 days and another 211 days after the last dose of study drug due to cancer relapse and pneumonia respectively (not related to study drug). Based on a review of the safety and pharmacokinetic data, the DSMC has recommended that the study proceed to enroll Cohort 3. Source: Press Release More on Theriva Biologics Seeking Alpha's Quant Rating on Theriva Biologics Historical earnings data for Theriva Biologics Financial
Show less
Read more
Impact Snapshot
Event Time:
TOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TOVX alerts
High impacting Theriva Biologics, Inc. news events
Weekly update
A roundup of the hottest topics
TOVX
News
- SOHM, Inc. Announces Allowances Of Japanese Patent Claims Received from Japan's Patent Office (???, Tokkyocho, JPO) Protecting Transformative SOHM-ABBIE Genome Edited, SAGE Recombinant-Organisms, -Cells, -Secretomes, -Exosomes [Yahoo! Finance]Yahoo! Finance
- Theriva Biologics GAAP EPS of -$6.81 [Seeking Alpha]Seeking Alpha
- Theriva™ Biologics Reports Third Quarter 2024 Operational Highlights and Financial ResultsGlobeNewswire
- Theriva Biologics Selected as Finalist in International Competition for Merck KGaA's EMEA Advance Biotech GrantGlobeNewswire
- Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of RetinoblastomaGlobeNewswire
TOVX
Analyst Actions
- 11/13/24 - Maxim Group
TOVX
Sec Filings
- 11/20/24 - Form S-8
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- TOVX's page on the SEC website